Komori
Share Issuance and Disposal4584Kidswell Bio CorporationPharmaceuticals

Notice Concerning the Monthly Exercise Status of the 4th Series of Unsecured Convertible Bonds with Stock Acquisition Rights and the 23rd Series of Stock Acquisition Rights through a Third-Party Allotment

During March 2026, there were no conversions or exercises of the 4th Unsecured Convertible Bond-Type Bonds with Stock Acquisition Rights and no exercises of the 23rd Stock Acquisition Rights, resulting in 0 shares delivered. The unexercised balance was unchanged from the end of the previous month.

Worth reading
34Immaterial
Scored from 2 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
0
Shares
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Monthly exercise status report for the 4th Unsecured Convertible Bond-Type Bonds with Stock Acquisition Rights and the 23rd Stock Acquisition Rights issued through a third-party allotment

発行・処分する株式数0Shares

0 shares (number of shares delivered during the month)

発行済株式総数

0% (exercise ratio subject to exercise restrictions)

The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.

Terms of the stock acquisition rights
Number of Stock Acquisition Rights
23rd Stock Acquisition Rights: 13,746 rights remaining unexercised (1,374,600 shares), with 0 rights exercised during the month; 4th Unsecured Convertible Bond-Type Bonds with Stock Acquisition Rights: ¥125 million remaining unexercised, with a total face value of ¥0 exercised during the month
Procedures under the Corporate Code of Conduct
Report on compliance with exercise restrictions under Article 434 of the Tokyo Stock Exchange's Rules for Listing of Securities and the Japan Securities Dealers Association's Rules Concerning the Handling of Third-Party Allotments
Most recent equity financing
4th Unsecured Convertible Bond-Type Bonds with Stock Acquisition Rights: issued on 14 July 2022; 23rd Stock Acquisition Rights: issued on 14 January 2025
Details of issuance or disposal
ItemDetails
Type of issuance or disposalMonthly exercise status report for the 4th Unsecured Convertible Bond-Type Bonds with Stock Acquisition Rights and the 23rd Stock Acquisition Rights issued through a third-party allotment
Number of shares to be issued or disposed of0 shares (number of shares delivered during the month)
Dilution Rate0% (exercise ratio subject to exercise restrictions)
Number of Stock Acquisition Rights23rd Stock Acquisition Rights: 13,746 rights remaining unexercised (1,374,600 shares), with 0 rights exercised during the month; 4th Unsecured Convertible Bond-Type Bonds with Stock Acquisition Rights: ¥125 million remaining unexercised, with a total face value of ¥0 exercised during the month
Procedures under the Corporate Code of ConductReport on compliance with exercise restrictions under Article 434 of the Tokyo Stock Exchange's Rules for Listing of Securities and the Japan Securities Dealers Association's Rules Concerning the Handling of Third-Party Allotments
Most recent equity financing4th Unsecured Convertible Bond-Type Bonds with Stock Acquisition Rights: issued on 14 July 2022; 23rd Stock Acquisition Rights: issued on 14 January 2025
Items this document does not state (22)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allotteeIntended allottee's holding policyTotal number of issued sharesBasis for determining the amount to be paidExercise priceExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The company is reporting the monthly exercise status for March 2026, but does not state why there were no exercises.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Concerning the Monthly Exercise Status of the 4th Series of Unsecured Convertible Bonds with Stock Acquisition Rights and the 23rd Series of Stock Acquisition Rights through a Third-Party Allotment | Kidswell Bio Corporation (4584) timely disclosure | Komori